8-K: INBS Reports Strong Q4 Revenue Growth, FDA Progress

Intelligent Bio Solutions Inc. announced preliminary fiscal fourth quarter 2025 revenue growth of approximately 16% sequentially and year-over-year, alongside significant progress on U.S. FDA 510(k) clearance for its opiate test system.

Summary

• Preliminary, unaudited revenue for fiscal Q4 2025 (ended June 30, 2025) shows approximately 16% sequential and year-over-year growth.
• Revenue growth is attributed to continued demand for higher-margin cartridge sales and steady account growth.
• Submitted FDA 510(k) application for its opiate test system (codeine), supported by new scientific and clinical validation data.
• Completed multilingual upgrades to the Intelligent Fingerprinting Drug Screening System to support broader global adoption.
• Launched localized websites and enhanced CRM workflows to improve partner and end-user engagement across Europe, the Middle East, and Latin America.
• Full financial results for fiscal Q4 and full year 2025 are expected to be disclosed in the Annual Report on Form 10-K, anticipated during the week commencing August 11, 2025.

Sentiment

Score: 8

Explanation: The filing reports strong preliminary revenue growth and significant progress on key strategic initiatives like FDA clearance and global expansion, indicating positive momentum for the company.

Positives

• Anticipated fiscal fourth quarter 2025 revenue growth of approximately 16% sequentially and year-over-year.
• Preliminary results indicate sequential revenue growth over both the fiscal third and second quarters.
• Strong demand for higher-margin cartridge sales and steady account growth.
• Significant progress on the regulatory pathway with FDA 510(k) application submission for the opiate test system.
• Strengthened global readiness through multilingual system upgrades and localization efforts.

Negatives

• None identified in the filing.

Risks

• Forward-looking statements involve known and unknown risks, uncertainties, and other factors.
• Ability to successfully develop and commercialize drug and diagnostic tests.
• Ability to realize commercial benefit from partnerships and collaborations.
• Ability to secure regulatory approvals.

Future Outlook

The company anticipates continued demand for its higher-margin cartridge sales and steady account growth. Full financial results for the fiscal fourth quarter and full year ended June 30, 2025, are expected to be disclosed in the upcoming Annual Report on Form 10-K, anticipated to be filed during the week commencing August 11, 2025. The company's future success depends on its ability to develop and commercialize its tests, benefit from partnerships, and secure regulatory approvals.

Management Comments

• "Fiscal 2025 represented a year of disciplined execution and strategic investment."
• "For the fiscal fourth quarter, we expect to report another quarter of sequential and year-over-year revenue growth."
• "In addition to our strong revenue performance, during the quarter we also made significant progress on the regulatory pathway in seeking U.S. FDA 510(k) clearance and continued scaling our operations globally with system upgrades and localization."

Industry Context

The announcement highlights Intelligent Bio Solutions' advancements in the medical technology and diagnostic testing sector, particularly in non-invasive drug screening. The focus on FDA clearance and global expansion reflects a strategic push to capture market share in the growing demand for rapid, hygienic, and cost-effective workplace drug testing solutions, aligning with broader industry trends towards more efficient and less intrusive diagnostic methods.

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or results to benchmark against global industry standards. It focuses on internal growth metrics and operational milestones.

Stakeholder Impact

• Shareholders: Positive preliminary revenue results and strategic progress could lead to increased investor confidence and potential share price appreciation.
• Customers: Enhanced global readiness, multilingual system upgrades, and localized websites aim to improve engagement and service for existing and new customers.
• Employees: Continued operational momentum and growth may indicate job stability and potential for expansion.

Next Steps

• Completion of year-end financial close process.
• Disclosure of full financial results for fiscal Q4 and full year 2025 in the Annual Report on Form 10-K.
• Filing of Annual Report on Form 10-K with the SEC during the week commencing August 11, 2025.
• Continued efforts to secure U.S. FDA 510(k) clearance for planned U.S. market entry.
• Further scaling global operations.

Key Dates

Recommendation

The company reported strong preliminary revenue growth of approximately 16% both sequentially and year-over-year, driven by high-margin product sales and account growth. Crucially, significant progress was made on the FDA 510(k) clearance for its opiate test system, which is a major catalyst for U.S. market entry. Global operational enhancements also position the company for broader adoption. These factors indicate strong operational momentum and potential for future growth, making it an attractive investment.

Keywords

Intelligent Bio Solutions, INBS, Medical Technology, Drug Screening, Fingerprint Testing, FDA 510(k), Revenue Growth, Biotechnology, Diagnostic Tests, Workplace Testing